Targacept, Inc., a biopharmaceutical company, engages in the development of novel neuronal nicotinic receptors (NNR) Therapeutics to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. The company’s NNR Therapeutics selectively target a class of receptors known as neuronal nicotinic receptors, which it refers to as NNRs. TC-6499 TC-6499 is a small molecule that modulates the activity of the a3ß4 and other NNRs as an agonist the company is conducting an exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a disorder, which is often debilitating and chronic, and that slows or stops the passage of food from the stomach to the small intestine. TC-6683 TC-6683 is a novel small molecule that modulates the activity of the a4ß2 NNR. TC-5619 and TC-6987 TC-5619 and TC-6987 are novel small molecules that are highly selective for the a7 NNR. The a7 NNR has been shown to play a role in a variety of biological pathways associated with various diseases and disorders. The company completed in 2013 a Phase 2b clinical trial of TC-5619 in negative symptoms and cognitive dysfunction in schizophrenia. TC-1734 TC-1734 is a wholly-owned novel small molecule that modulates the activity of the a4ß2 NNR. In 2014, the company announced that its Phase 2b clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease did not meet its primary endpoint. The company completed in 2014 a Phase 2b clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. TC-5214 TC-5214 acts as an antagonist on the a3ß4 NNRs. The company completed in 2014 a Phase 2b clinical trial of TC-5214 in overactive bladder. Strategy The key elements of the company’s strategy are to expand its pipeline of product candidates deliberatively; and seek value for its pipeline of NNR Therapeutics. Patents and Proprietary Rights As of February 28, 2015, the company’s issued patents and pending patent applications in the United States and foreign counterparts include composition of matter coverage on various different structural families of compounds. License Agreements Pursuant to a license agreement with University of South Florida Research Foundation (USFRF), the company holds an exclusive worldwide license under patents and patent applications owned by USFRF to develop and commercialize TC-5214, mecamylamine hydrochloride and other specified compounds. The licensed patent rights include issued patents covering the pharmaceutical composition of TC-5214. Regulatory Matters The company’s product candidates must be approved by the U.S. Food and Drug Administration through the new drug application process before they may be legally marketed in the United States. History Targacept, Inc., a Delaware corporation, was founded in 1997. The company was incorporated in 1997.
targacept inc (TRGT:NASDAQ GS)
100 North Main Street
Winston-Salem, NC 27101
|Eli Lilly & Co||$84.51 USD||-0.03|
|Novartis AG||SFr.100.40 CHF||+0.40|
|Pfizer Inc||$36.06 USD||+0.33|
|ProMIS Neurosciences Inc||C$0.07 CAD||0.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact TARGACEPT INC, please visit www.targacept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.